Colestipol
- Atc Codes:C10AC02
- CAS Codes:37296-80-3#26658-42-4
- PHARMGKB ID:37296-80-3#26658-42-4
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Belgium: Colestid; Denmark: Lestid; Germany: Cholestabyl; Luxembourg: Colestid; Poland: Colestid; Portugal: Colestid; Spain: Colestid; Sweden: Lestid; UK: Colestid.
North America
Canada: Colestid; USA: Colestid, Colestipol.
Drug combinations
Chemistry
Colestipol Hydrochloride: Because of the highly cross-linked and insoluble nature of this basic anion-exchange resin, no graphic formula has been assigned, and no molecular weight information is available. (1) Colestipol hydrochloride; (2) Copolymer of diethylenetriamine and 1-chloro-2,3-epoxypropane, hydrochloride CAS-37296-80-3; CAS-26658-42-4 (colestipol)(1969).
Pharmacologic Category
Antilipemic Agents; Bile Acid Sequestrants. (ATC-Code: C10AC02).
Mechanism of action
Binds to bile acids in the intestine and forms a nonabsorbable complex. Thus, bile acids are partially removed from enterohepatic circulation and conversion of cholesterol to bile acids in the liver is increased. This enhanced demand for cholesterol in liver cells causes a compensatory increase in hepatic uptake (and thus systemic clearance) of circulating LDL-C. Serum triglyceride concentrations may remain unchanged or increase slightly (5-10%). Antilipemic effects are additive when used with lovastatin or niacin.
Therapeutic use
Primary hypercholesterolemia. Arteriolosclerosis. Pruritus associated with elevated levels of bile acids. To decrease plasma half-life of digoxin in toxicity.
Pregnancy and lactiation implications
Safe use of colestipol during pregnancy not established and should be used in women who are or may become pregnant only when potential benefits justify possible risks. The possible lack of proper vitamin absorption associated with colestipol therapy may have an effect on nursing infants (use with caution in nursing women).
Unlabeled use
Contraindications
Hypersensitivity to bile acid sequestering resins or any component of the formulation. Bowel obstruction.
Warnings and precautions
Chronic use may be associated with bleeding problems. May produce or exacerbate constipation problems (fecal impaction may occur; hemorrhoids may be worsened). May decrease absorption of other medicines. May interfere with fat-soluble vitamins (A, D, E, K) and folic acid. Some forms may contain phenylalanine. May produce increased prothrombin time.